« Return to News | Drug Sponsors

Valeant to acquire Afexa Life Sciences

Wednesday, August 31, 2011 12:25 PM

Valeant Pharmaceuticals International has agreed to acquire fellow Canadian firm Afexa Life Sciences for $76 million in cash, a figure that comfortably tops an offer made by another company based in Canada, Paladin Labs, according to PharmaTimes.

Afexa chairman William White said the Paladin offer is "inadequate even to reflect the value of our marquee product [Cold-Fx] and gives little to no value of our growth opportunities through new products and new markets.” However the Valeant bid has been accepted unanimously by the board.

As part of the agreement, Afexa, which is based in Edmonton, has a 30 days 'go-shop' period to a find a better offer. Valeant has rights to match any bid that materializes or be paid a $3.75-million termination fee if Afexa chooses another proposal.

Share:          
CLINICAL TRIAL RESOURCES

Search:

NEWS ONLINE ARCHIVE

Browse by:

CWWeekly

December 17

Medici Global says its Alzheimer's Facebook page demonstrates the need for more early detection trials

Analysts: Expect more equity purchases of CROs in 2013

Already a subscriber?
Log in to your digital subscription.

Subscribe to CWWeekly.

The CenterWatch Monthly

January 2013

Parexel celebrates 30 years of change, growth
CRO's founder and chairman reflects on challenges of the past, present and future

Strategies for increasing patient diversity in trials
Sponsors look to improve racial, ethnic recruitment without going overseas

Already a subscriber?
Log in to your digital subscription.

Purchase the January issue.

Subscribe to The CenterWatch Monthly.

December 2012

Publicity, regulation tightening reins on use of KOLs
Debate rages over need to revamp how sponsors use, pay medical experts

Time may be right to makeover the investigator brochure
Size, complexity prevent critical document from being thoroughly read

Already a subscriber?
Log in to your digital subscription.

Purchase the December issue.

Subscribe to The CenterWatch Monthly.

JobWatch centerwatch.com/jobwatch

Featured Jobs

More Jobs

 

Copyright © 1995-2013 CenterWatch.